.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Cantor Fitzgerald
Express Scripts
Chubb
Deloitte
McKinsey
Argus Health
Merck
Fish and Richardson

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,723,303 protect, and when does it expire?


Patent ► Subscribe protects OPTISON and is included in one NDA.

This patent has thirty-nine patent family members in twenty-seven countries.

Summary for Patent: ► Subscribe

Title: Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
Abstract:Agents for use in ultrasound contrast include protein microspheres in which a gas such as perfluoropropane, perfluorobutane or perfluoropentane is contained.
Inventor(s): Quay; Steven C (Pacific Palisades, CA)
Assignee: Amersham Health, AS (Oslo, NO)
Application Number:08/466,104
Patent Claim Types:
see list of patent claims
Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 1997RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,875,420 Method of ultrasound imaging► Subscribe
5,393,524 Methods for selecting and using gases as ultrasound contrast media► Subscribe
5,558,854 Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas► Subscribe
5,558,094 Methods for using persistent gases as ultrasound contrast media► Subscribe
6,620,404 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media► Subscribe
5,666,526 Method and system for supporting scrollable, updatable database queries► Subscribe
6,156,292 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media► Subscribe
5,409,688 Gaseous ultrasound contrast media► Subscribe
5,573,751 Persistent gaseous bubbles as ultrasound contrast media► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria191346► Subscribe
Australia2550392► Subscribe
Australia3995997► Subscribe
Australia679428► Subscribe
Brazil1100167► Subscribe
Canada2119129► Subscribe
Canada2273140► Subscribe
China1054545► Subscribe
China1073104► Subscribe
China1264600► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Farmers Insurance
Mallinckrodt
Citi
Dow
Merck
QuintilesIMS
AstraZeneca
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot